Influence of Digital Intervention Messaging on Influenza Vaccination Rates Among Adults With Cardiovascular Disease in the United States: Decentralized Randomized Controlled Trial.

cardiovascular disease digital intervention digital messaging immunization influenza mHealth mobile health public health randomized trial vaccination

Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
07 10 2022
Historique:
received: 13 04 2022
accepted: 31 07 2022
revised: 21 06 2022
entrez: 7 10 2022
pubmed: 8 10 2022
medline: 12 10 2022
Statut: epublish

Résumé

Seasonal influenza affects 5% to 15% of Americans annually, resulting in preventable deaths and substantial economic impact. Influenza infection is particularly dangerous for people with cardiovascular disease, who therefore represent a priority group for vaccination campaigns. We aimed to assess the effects of digital intervention messaging on self-reported rates of seasonal influenza vaccination. This was a randomized, controlled, single-blind, and decentralized trial conducted at individual locations throughout the United States over the 2020-2021 influenza season. Adults with self-reported cardiovascular disease who were members of the Achievement mobile platform were randomized to receive or not receive a series of 6 patient-centered digital intervention messages promoting influenza vaccination. The primary end point was the between-group difference in self-reported vaccination rates at 6 months after randomization. Secondary outcomes included the levels of engagement with the messages and the relationship between vaccination rates and engagement with the messages. Subgroup analyses examined variation in intervention effects by race. Controlling for randomization group, we examined the impact of other predictors of vaccination status, including cardiovascular condition type, vaccine drivers or barriers, and vaccine knowledge. Of the 49,138 randomized participants, responses on the primary end point were available for 11,237 (22.87%; 5575 in the intervention group and 5662 in the control group) participants. The vaccination rate was significantly higher in the intervention group (3418/5575, 61.31%) than the control group (3355/5662, 59.25%; relative risk 1.03, 95% CI 1.004-1.066; P=.03). Participants who were older, more educated, and White or Asian were more likely to report being vaccinated. The intervention was effective among White participants (P=.004) but not among people of color (P=.42). The vaccination rate was 13 percentage points higher among participants who completed all 6 intervention messages versus none, and at least 2 completed messages appeared to be needed for effectiveness. Participants who reported a diagnosis of COVID-19 were more likely to be vaccinated for influenza regardless of treatment assignment. This personalized, evidence-based digital intervention was effective in increasing vaccination rates in this population of high-risk people with cardiovascular disease. ClinicalTrials.gov NCT04584645; https://clinicaltrials.gov/ct2/show/NCT04584645.

Sections du résumé

BACKGROUND
Seasonal influenza affects 5% to 15% of Americans annually, resulting in preventable deaths and substantial economic impact. Influenza infection is particularly dangerous for people with cardiovascular disease, who therefore represent a priority group for vaccination campaigns.
OBJECTIVE
We aimed to assess the effects of digital intervention messaging on self-reported rates of seasonal influenza vaccination.
METHODS
This was a randomized, controlled, single-blind, and decentralized trial conducted at individual locations throughout the United States over the 2020-2021 influenza season. Adults with self-reported cardiovascular disease who were members of the Achievement mobile platform were randomized to receive or not receive a series of 6 patient-centered digital intervention messages promoting influenza vaccination. The primary end point was the between-group difference in self-reported vaccination rates at 6 months after randomization. Secondary outcomes included the levels of engagement with the messages and the relationship between vaccination rates and engagement with the messages. Subgroup analyses examined variation in intervention effects by race. Controlling for randomization group, we examined the impact of other predictors of vaccination status, including cardiovascular condition type, vaccine drivers or barriers, and vaccine knowledge.
RESULTS
Of the 49,138 randomized participants, responses on the primary end point were available for 11,237 (22.87%; 5575 in the intervention group and 5662 in the control group) participants. The vaccination rate was significantly higher in the intervention group (3418/5575, 61.31%) than the control group (3355/5662, 59.25%; relative risk 1.03, 95% CI 1.004-1.066; P=.03). Participants who were older, more educated, and White or Asian were more likely to report being vaccinated. The intervention was effective among White participants (P=.004) but not among people of color (P=.42). The vaccination rate was 13 percentage points higher among participants who completed all 6 intervention messages versus none, and at least 2 completed messages appeared to be needed for effectiveness. Participants who reported a diagnosis of COVID-19 were more likely to be vaccinated for influenza regardless of treatment assignment.
CONCLUSIONS
This personalized, evidence-based digital intervention was effective in increasing vaccination rates in this population of high-risk people with cardiovascular disease.
TRIAL REGISTRATION
ClinicalTrials.gov NCT04584645; https://clinicaltrials.gov/ct2/show/NCT04584645.

Identifiants

pubmed: 36206046
pii: v24i10e38710
doi: 10.2196/38710
pmc: PMC9587491
doi:

Substances chimiques

Influenza Vaccines 0

Banques de données

ClinicalTrials.gov
['NCT04584645']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e38710

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK092926
Pays : United States

Informations de copyright

©Nell J Marshall, Jennifer L Lee, Jessica Schroeder, Wei-Nchih Lee, Jermyn See, Mohammad Madjid, Mrudula R Munagala, John D Piette, Litjen Tan, Orly Vardeny, Michael Greenberg, Jan Liska, Monica Mercer, Sandrine Samson. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 07.10.2022.

Références

Vaccine. 2020 Apr 16;38(18):3508-3514
pubmed: 31787410
PLoS One. 2018 Feb 14;13(2):e0192594
pubmed: 29444147
Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):
pubmed: 35105809
JAMA Intern Med. 2020 Jul 1;180(7):962-970
pubmed: 32421168
JAMA. 2013 Oct 23;310(16):1711-20
pubmed: 24150467
NPJ Digit Med. 2021 Sep 17;4(1):138
pubmed: 34535755
J Thorac Dis. 2009 Dec;1(1):51-4
pubmed: 22263004
Vaccine. 2017 Feb 1;35(5):842-848
pubmed: 28062124
Cochrane Database Syst Rev. 2015 May 05;(5):CD005050
pubmed: 25940444
J Am Heart Assoc. 2021 Mar 16;10(6):e019636
pubmed: 33719496
JAMA. 2014 Oct 15;312(15):1513-4
pubmed: 25167382
Ann Fam Med. 2017 Nov;15(6):507-514
pubmed: 29133488
Am J Public Health. 2014 Feb;104 Suppl 1:e7-12
pubmed: 24354839
N Engl J Med. 2018 Jan 25;378(4):345-353
pubmed: 29365305
Vaccine. 2018 Jun 22;36(27):3960-3966
pubmed: 29801998
Am J Health Promot. 2019 Jul;33(6):916-920
pubmed: 30630342
Clin Infect Dis. 2021 Mar 15;72(6):913-919
pubmed: 33033829
Vaccine. 2019 Jul 26;37(32):4594-4600
pubmed: 29699784
Am J Prev Med. 2019 Oct;57(4):e125-e133
pubmed: 31471001
BMJ Open. 2016 Feb 19;6(2):e010069
pubmed: 26895984
J Med Internet Res. 2020 Sep 25;22(9):e16373
pubmed: 32975529
Am J Prev Med. 2017 Dec;53(6):845-853
pubmed: 28867143
J Gen Intern Med. 2018 May;33(5):659-667
pubmed: 29383550
Curr Atheroscler Rep. 2021 Oct 21;23(12):78
pubmed: 34671861
Circulation. 2021 Feb 23;143(8):e254-e743
pubmed: 33501848
Heart. 2016 Dec 15;102(24):1953-1956
pubmed: 27686519
Ann Intern Med. 2020 Oct 20;173(8):605-613
pubmed: 32833488
PLoS One. 2017 Jan 26;12(1):e0170550
pubmed: 28125629
JMIR Mhealth Uhealth. 2020 Jan 14;8(1):e14512
pubmed: 31934874
Am J Prev Med. 2018 Aug;55(2):231-239
pubmed: 29910118
Obstet Gynecol. 2013 Apr;121(4):734-740
pubmed: 23635672

Auteurs

Nell J Marshall (NJ)

Evidation Health, Inc, San Mateo, CA, United States.

Jennifer L Lee (JL)

Evidation Health, Inc, San Mateo, CA, United States.

Jessica Schroeder (J)

Evidation Health, Inc, San Mateo, CA, United States.

Wei-Nchih Lee (WN)

Evidation Health, Inc, San Mateo, CA, United States.

Jermyn See (J)

Evidation Health, Inc, San Mateo, CA, United States.

Mohammad Madjid (M)

David Geffen School of Medicine, University of California, Los Angeles, CA, United States.

Mrudula R Munagala (MR)

Department of Cardiology, University of Miami, Miami, FL, United States.

John D Piette (JD)

Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, United States.

Litjen Tan (L)

Immunize.org, St. Paul, MN, United States.

Orly Vardeny (O)

Center for Care Delivery and Outcomes Research, Veterans Health Administration, Minneapolis, MN, United States.

Michael Greenberg (M)

Sanofi, Swiftwater, PA, United States.

Monica Mercer (M)

Sanofi, Swiftwater, PA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH